Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2018
At a glance
- Drugs BI 690517 (Primary) ; Eplerenone
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 18 Apr 2018 Planned number of patients changed from 126 to 105.
- 05 Feb 2018 Planned End Date changed from 24 Sep 2018 to 30 Jun 2019.
- 05 Feb 2018 Planned primary completion date changed from 24 Sep 2018 to 30 Jun 2019.